Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dl-amphetamine Sulfate
2. Amphetamine Sulphate
3. Phenaminum
4. 60-13-9
5. Amphamine Sulfate
6. Amphetamini Sulfas
7. Dl-phenamine Sulfate
8. Dl-amphetamine Sulphate
9. Amphetaminium Sulfuricum
10. Desoxynorephedrine Sulfate
11. (+-)-amphetamine Sulfate
12. Dl-amphetamine Hydrogen Sulfate
13. (+-)-phenisopropylamine Sulfate
14. Amfetamine Sulfate
15. Amphetamine Sulfate [usp]
16. Dl-1-phenyl-2-aminopropane Sulfate
17. (+-)-2-amino-1-phenylpropane Sulfate
18. (+-)-alpha-methylphenethylamine Sulfate (2:1)
19. 6dpv8nk46s
20. 1-phenylpropan-2-amine Sulfate (2:1)
21. Amphetamine Sulfate (usp)
22. Fenopromin Sulfate
23. Penamine (van)
24. Ccris 3644
25. 1-phenyl-2-aminopropane Sulfate
26. Cerm 1767
27. Razemisches Phenylaminopropansulfat
28. Dl-alpha-methylphenethylamine Sulfate
29. Einecs 200-457-8
30. Unii-6dpv8nk46s
31. Nsc 170999
32. Dl-amphetamine Sulfate Salt
33. Benzadrine
34. Alpha-methylphenethylamine Sulfate, (+-)-
35. Benzedrine (tn)
36. Evekeo (tn)
37. Evekeo Odt
38. Rac-amphetamine Sulphate
39. D-amphetamine Sulfate Salt
40. Schembl41204
41. Amphetamine Sulfate [mi]
42. Dtxsid4020082
43. Phenethylamine, Alpha-methyl-, Sulfate (2:1), (+-)-
44. Chebi:51063
45. Amfetamine Sulfate [mart.]
46. Amphetamine Sulfate [vandf]
47. Amfetamine Sulfate [who-dd]
48. Bis{1-phenylpropan-2-amine} Sulfate
49. Amfetamine Sulfate [ep Impurity]
50. Amfetamine Sulfate [ep Monograph]
51. Amphetamine Sulfate [orange Book]
52. .beta.-phenylisopyropylaminesulfate
53. Benzeneethanamine, Alpha-methyl-, Sulfate
54. Amphetamine Sulfate [usp Monograph]
55. Amfetamine Sulfate [incb:green List]
56. Delcobese Component Amphetamine Sulfate
57. D02074
58. (+/-)-2-amino-1-phenylpropane Sulfate
59. (+/-)-2-amino-1-phenylpropane Sulphate
60. Amphetamine Sulfate Component Of Delcobese
61. Q21270844
62. (+/-)-.alpha.-methylphenethylamine Sulfate (2:1)
63. (+/-)-.alpha.-methylphenethylamine Sulphate (2:1)
64. Benzeneethanamine, .alpha.-methyl-, Sulfate (2:1), (+/-)-
65. Benzeneethanamine, .alpha.-methyl-, Sulphate (2:1), (+/-)-
66. Dl-amphetamine Sulfate Salt Solution, Drug Standard, 1.0 Mg/ml In Methanol
67. 2-(tetrahydro-furan-2-yl)-n-(3-trifluoromethyl-phenyl)-succinamicacid
68. 156-31-0
1. Amfetamine
2. Mydrial
3. Desoxynorephedrine
4. L Amphetamine
Molecular Weight | 368.5 g/mol |
---|---|
Molecular Formula | C18H28N2O4S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 368.17697855 g/mol |
Monoisotopic Mass | 368.17697855 g/mol |
Topological Polar Surface Area | 135 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 166 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14783
Submission : 2000-03-17
Status : Active
Type : II
NDC Package Code : 49812-0058
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15089
Submission : 2000-10-13
Status : Active
Type : II
NDC Package Code : 49812-0059
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 23583
Submission : 2010-03-04
Status : Active
Type : II
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 24048
Submission : 2010-07-08
Status : Active
Type : II
Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 15385
Submission : 2001-04-18
Status : Active
Type : II
Certificate Number : R0-CEP 2020-076 - Rev 00
Issue Date : 2021-07-26
Type : Chemical
Substance Number : 2752
Status : Valid
NDC Package Code : 0406-4942
Start Marketing Date : 2013-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-08
Pay. Date : 2013-05-31
DMF Number : 15425
Submission : 2001-05-09
Status : Active
Type : II
NDC Package Code : 0406-1950
Start Marketing Date : 2013-04-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-04
Pay. Date : 2015-08-27
DMF Number : 29601
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3939
Start Marketing Date : 2023-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-24
Pay. Date : 2015-08-27
DMF Number : 29604
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3936
Start Marketing Date : 2022-12-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-22
Pay. Date : 2023-11-03
DMF Number : 38836
Submission : 2023-10-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5378
Submission : 1984-02-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15089
Submission : 2000-10-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14783
Submission : 2000-03-17
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 24048
Submission : 2010-07-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 23583
Submission : 2010-03-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2314
Submission : 1974-08-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15338
Submission : 2001-02-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-18
Pay. Date : 2012-12-12
DMF Number : 15308
Submission : 2001-02-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-18
Pay. Date : 2012-12-12
DMF Number : 15307
Submission : 2001-02-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15340
Submission : 2001-02-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5378
Submission : 1984-02-09
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
dl-1-Chloro-1-phenyl-2-aminopropane Hydrochloride
CAS Number : 25394-33-6
End Use API : Amphetamine Sulfate
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
CAS Number : 3182-95-4
End Use API : Amphetamine Sulfate
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
Phenyl Acetone OR 1-Phenyl-2-Peopanone
CAS Number : 103-79-7
End Use API : Amphetamine Sulfate
About The Company : Maisuriya Pharma Solutions is a research-driven & technology-oriented company. Continuous innovations & improvement are the lifeblood of our business. Our major...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Amphetamine, Dextroamphetamine Sulfate, Dextroamphetami...
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 184
2021 Revenue in Millions : 171
Growth (%) : 8
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
54
PharmaCompass offers a list of Amphetamine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Amphetamine Sulfate manufacturer or Amphetamine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Amphetamine Sulfate manufacturer or Amphetamine Sulfate supplier.
PharmaCompass also assists you with knowing the Amphetamine Sulfate API Price utilized in the formulation of products. Amphetamine Sulfate API Price is not always fixed or binding as the Amphetamine Sulfate Price is obtained through a variety of data sources. The Amphetamine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ADDERALL XR 30-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ADDERALL XR 30-1, including repackagers and relabelers. The FDA regulates ADDERALL XR 30-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ADDERALL XR 30-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ADDERALL XR 30-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ADDERALL XR 30-1 supplier is an individual or a company that provides ADDERALL XR 30-1 active pharmaceutical ingredient (API) or ADDERALL XR 30-1 finished formulations upon request. The ADDERALL XR 30-1 suppliers may include ADDERALL XR 30-1 API manufacturers, exporters, distributors and traders.
click here to find a list of ADDERALL XR 30-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ADDERALL XR 30-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of ADDERALL XR 30-1 active pharmaceutical ingredient (API) in detail. Different forms of ADDERALL XR 30-1 DMFs exist exist since differing nations have different regulations, such as ADDERALL XR 30-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ADDERALL XR 30-1 DMF submitted to regulatory agencies in the US is known as a USDMF. ADDERALL XR 30-1 USDMF includes data on ADDERALL XR 30-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ADDERALL XR 30-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ADDERALL XR 30-1 suppliers with USDMF on PharmaCompass.
A ADDERALL XR 30-1 CEP of the European Pharmacopoeia monograph is often referred to as a ADDERALL XR 30-1 Certificate of Suitability (COS). The purpose of a ADDERALL XR 30-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ADDERALL XR 30-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ADDERALL XR 30-1 to their clients by showing that a ADDERALL XR 30-1 CEP has been issued for it. The manufacturer submits a ADDERALL XR 30-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a ADDERALL XR 30-1 CEP holder for the record. Additionally, the data presented in the ADDERALL XR 30-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ADDERALL XR 30-1 DMF.
A ADDERALL XR 30-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ADDERALL XR 30-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ADDERALL XR 30-1 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ADDERALL XR 30-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ADDERALL XR 30-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ADDERALL XR 30-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ADDERALL XR 30-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ADDERALL XR 30-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ADDERALL XR 30-1 suppliers with NDC on PharmaCompass.
ADDERALL XR 30-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ADDERALL XR 30-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ADDERALL XR 30-1 GMP manufacturer or ADDERALL XR 30-1 GMP API supplier for your needs.
A ADDERALL XR 30-1 CoA (Certificate of Analysis) is a formal document that attests to ADDERALL XR 30-1's compliance with ADDERALL XR 30-1 specifications and serves as a tool for batch-level quality control.
ADDERALL XR 30-1 CoA mostly includes findings from lab analyses of a specific batch. For each ADDERALL XR 30-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ADDERALL XR 30-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (ADDERALL XR 30-1 EP), ADDERALL XR 30-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ADDERALL XR 30-1 USP).